The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Functional impact of somatic mutations in early-onset (EO) versus average onset (AO) microsatellite stable (MSS) stage III colorectal cancer (CRC).
 
Emily Harrold
Consulting or Advisory Role - Pfizer
 
Mark Solter
No Relationships to Disclose
 
Henry S. Walch
No Relationships to Disclose
 
Walid Khaled Chatila
No Relationships to Disclose
 
Fergus Keane
No Relationships to Disclose
 
Melissa Amy Lumish
No Relationships to Disclose
 
Rona Yaeger
Consulting or Advisory Role - Array BioPharma; Mirati Therapeutics; Natera
Research Funding - Array BioPharma (Inst); Boehringer Ingelheim (Inst); Mirati Therapeutics (Inst); Pfizer (Inst)
 
Jill A. Weiss
No Relationships to Disclose
 
Randze Lerie Palmaira
No Relationships to Disclose
 
Asha Krishnan
No Relationships to Disclose
 
Luis A. Diaz
Leadership - Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Amgen (I); Delfi Diagnostics; Four Paws; Jounce Therapeutics; Kinnate Biopharma; Neophore; Personal Genome Diagnostics; Seer; Thrive Earlier Detection Corp; Zydecom
Consulting or Advisory Role - Four Paws; Innovatus Capital Partners; Kinnate Biopharma; Merck; Neophore; Personal Genome Diagnostics; Seer; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
 
Zsofia Kinga Stadler
Consulting or Advisory Role - Adverum (I); Alcon (I); Gyroscope (I); Neurogene (I); Regenxbio (I)
 
Andrea Cercek
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Incyte; Janssen; Merck; Seagen
Research Funding - GlaxoSmithKline; Rgenix (Inst); Seagen